PARAMUS, N.J., Nov.20, 2012 \/PRNewswire\/ --PROTEONOMIX, INC. (PROT), a biotechnology company (the \"Company\") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121. <\/p>\n
Michael Cohen, the Chief Executive Officer of the Company stated: \"At least thirty (30) patients have been screened so far pursuant to inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol. The initiation of screening is the first step towards commencement of the clinical trial of UMK-121.\" <\/p>\n
About Proteonomix, Inc. <\/p>\n
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at http:\/\/www.proteonomix.com<\/a> and http:\/\/www.proteoderm.com<\/a>. <\/p>\n Forward-looking statements: <\/p>\n Certain statements contained herein are \"forward-looking statements\" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made. <\/p>\n<\/p>\n More here: PARAMUS, N.J., Nov.20, 2012 \/PRNewswire\/ --PROTEONOMIX, INC. (PROT), a biotechnology company (the \"Company\") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121. Continue reading
\nProteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"